Similarity is based on the correlation of the price action of the past 100 trading sessions.
The reference chart (RIME) is shown first. Other charts are sorted by their correlation and the most similar chart is ranked highest.
Algorhythm Holdings, Inc., together with its subsidiaries, engages in the development, marketing, and sale of consumer karaoke audio equipment, accessories, and musical recordings in North America, Australia, the United Kingdom, Europe, and internationally.
It offers karaoke products under the Singing Machine brand; licensed karaoke microphone products under the Carpool Karaoke brand; microphone and accessories, and portable Bluetooth microphones under the Party Machine brand; music entertainment singing machines for children under the brand Singing Machine Kids; connected vehicle karaoke devices; and karaoke music subscription services for the iOS and Android platforms, as well as a web-based download store and integrated streaming services for hardware.
The company primarily sells its products to retailers, including national chains, warehouse clubs, department stores, lifestyle merchants, specialty stores, and direct mail catalogs and showrooms.
The company was formerly known as The Singing Machine Company, Inc. and changed its name to Algorhythm Holdings, Inc. in September 2024.
Algorhythm Holdings, Inc. was incorporated in 1982 and is headquartered in Fort Lauderdale, Florida.
Headquartered in Virginia Beach, Virginia, Wheeler Real Estate Investment Trust, Inc. (Nasdaq: WHLR) is a fully-integrated, self-managed commercial real estate investment company focused on owning, leasing and operating income-producing retail properties with a primary focus on grocery-anchored centers.
WHLR's portfolio contains well-located, potentially dominant retail properties in secondary and tertiary markets that generate attractive, risk-adjusted returns.
WHLR's common stock, Series B convertible preferred stock (Series B Preferred Stock and, together with the Series D Preferred Stock, the Preferred Stock), Series D Preferred Stock, and Convertible Notes trade publicly on Nasdaq under the symbols WHLR, WHLRP, WHLRD, and WHLRL, respectively.
New Era Helium, Inc. engages in the exploration, development, and production of helium, natural gas, and natural gas liquids in North America.
It holds a portfolio of approximately 137,000 acres in Southeast New Mexico.
The company is based in Midland, Texas.
Color Star Technology Co., Ltd., an entertainment and education company, provides online entertainment performances and music education services.
The company operates Color World, an online platform of curriculum that includes music, sports, animation, painting and calligraphy, film and television, life skills, etc.
Its Color World platform provides celebrity lectures, celebrity concert videos, celebrity peripheral products, and artist interactive communication services.
It offers construction management consulting services.
The company was formerly known as Huitao Technology Co., Ltd. and changed its name to Color Star Technology Co., Ltd. in May 2020.
Color Star Technology Co., Ltd. was founded in 2002 and is based in New York, New York.
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies.
The company was incorporated in 2021 and is based in South San Francisco, California.
Graphjet Technology Sdn.
Bhd. engages in the production of graphene and graphite raw materials.
It utilizes palm kernel shells to produce single layer graphene and artificial graphite.
Graphjet Technology Sdn.
Bhd. is based in Kuala Lumpur, Malaysia.
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform.
Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.
The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Cyngn Inc., an autonomous vehicle (AV) technology company, develops autonomous driving software in the United States.
The company develops Enterprise Autonomy Suite, which consists of DriveMod, a modular industrial vehicle autonomous driving software; and Cyngn Insight, a customer-facing tool suite for monitoring and managing AV fleets and generating/aggregating/analyzing data.
It also develops Cyngn Evolve, an internal tool suite and infrastructure that facilitates artificial intelligence and machine learning training to continuously enhance algorithms and models, as well as provides a simulation framework to ensure that data collected in the field can be applied to validating new releases.
Cyngn Inc. was incorporated in 2013 and is headquartered in Menlo Park, California.
Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions in the United States and internationally.
The company operates in truck and energy units.
It commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector.
In addition, it develops a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers.
Further, its products include Nikola Tre Class 8 truck and the Nikola's Class 8 FCEV.
Additionally, the company assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers.
Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.
On February 19, 2025, Nikola Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in theU. S.
Bankruptcy Court for the District of Delaware.
Blue Hat Interactive Entertainment Technology engages in bulk commodity trading business in the People's Republic of China.
It operates through three segments: Diamond Trading, Commodity Trading, and Information Services.
The company engages in the commodity trading business, such as chemicals primarily ethanol; and jewelry, which includes diamonds, gold, etc.
Its distribution channels include domestic distributors, e-commerce platforms, supermarkets, and export distributors.
Blue Hat Interactive Entertainment Technology was incorporated in 2010 and is based in Xiamen, China.
Contango Ore, Inc., an exploration stage company, engages in the exploration and development of mineral properties in Alaska, the United States.
It primarily explores for gold, silver, and copper ores.
The company was founded in 2009 and is headquartered in Fairbanks, Alaska.
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.
The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development; Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways; and Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33.
Zura Bio Limited was founded in 2021 and is based in Henderson, Nevada.
BTC Digital Ltd. a crypto asset technology company engages in bitcoin mining business.
It is also involved in mining machines resale and rental business.
The company was formerly known as Meten Holding Group Ltd. and changed its name to BTC Digital Ltd. in August 2023.
The company was founded in 2006 and is headquartered in Shenzhen, China.
Zhibao Technology Inc., through its subsidiaries, provides digital insurance brokerage services in China.
It also offers managing general underwriter services; healthcare; and offline insurance brokerage consulting services.
The company was founded in 2015 and is based in Shanghai, China.
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies.
The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.
Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus.
Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia.
The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer.
It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.
Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Creative Media & Community Trust Corporation (the "Company"), is a Maryland corporation and real estate investment trust ("REIT").
The Company primarily acquires, develops, owns and operates both premier multifamily properties situated in vibrant communities throughout the United States and Class A and creative office real assets in markets with similar business and employment characteristics to its multifamily investments.
The Company also owns one hotel in northern California and a lending platform that originates loans under the Small Business Administration ("SBA") 7(a) loan program.
The Company seeks to apply the expertise of CIM Group Management, LLC and its affiliates (collectively, "CIM Group") to the acquisition, development and operation of premier multifamily properties and creative office assets that cater to rapidly growing industries such as technology, media and entertainment in vibrant and emerging communities throughout the United States.
Creative Media & Community Trust Corporation operates as a subsidiary of CIM Group,L. P.
Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases.
The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain.
Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial.
It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.
In addition, the company's preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches.
It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases.
The company was founded in 2013 and is headquartered in South San Francisco, California.
LogicMark, Inc. provides personal emergency response systems (PERS), health communications devices, and Internet of Things (IoT) technology that creates a connected care platform in the United States.
The company's devices provide people with the ability to receive care at home and age independently and to check, manage, and monitor a loved one's health and safety remotely.
It also manufactures and distributes non-monitored and monitored personal emergency response systems, which are offered through the United States Veterans Health Administration (VHA), direct-to-consumers, healthcare durable medical equipment dealers and distributors, monitored security dealers and distributors, and its ecommerce website logicmark.com and Amazon.com.
The company was formerly known as Nxt-ID, Inc. and changed its name to LogicMark, Inc. in March 2022.
LogicMark, Inc. was founded in 2006 and is based in Louisville, Kentucky.
NewGenIvf Group Limited, through its subsidiaries, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, and Kyrgyzstan.
It provides invitro fertilization treatment, and surrogacy and ancillary caring services such as mitochondrial replacement (MRT) therapy in reproductive, intrauterine insemination, MRT techniques, ICSI, hysteroscopy, semen analysis, TESE, TESA, PESA, embryo transfer, sorting, washing and freezing, egg freezing, intrauterine insemination, and chromosome screening.
It also provides nutrition guidance, psychological counselling, acupuncture, and translation interpreters to supplement the IVF treatment as well as maternity caring service and documentation service.
The company was founded in 2010 and is based in Central, Hong Kong.
Vision Marine Technologies Inc. designs, develops, manufactures, rents, and sells electric boats in Canada, the United States, and internationally.
The company offers e-motion electric powertrain technology; e-motion electric outboard powertrain system; electric boats; and maintenance, repair, and customer support services, as well as manufactures customized boats.
The company also provides its products through website and distributors.
It serves original equipment manufacturers, retail customer, boat clubs, and boat rental operations.
The company was formerly known as Riopel Marine Inc. and changed its name to Vision Marine Technologies Inc. in April 2020.
Vision Marine Technologies Inc. was founded in 1995 and is headquartered in Boisbriand, Canada.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors.
It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio.
Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Vast Renewables Limited, a renewable energy company, develops and sells concentrated solar thermal power (CSP) systems.
It's CSP systems are used to generate, store, and dispatch electricity and industrial heat, as well as to enable the production of green fuels.
The company was incorporated in 2009 and is based in North Sydney, Australia.
Vast Renewables Limited operates as a subsidiary of Agcentral Energy Pty Limited.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors.
Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide.
Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.
The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them.
It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors.
Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Professional Diversity Network, Inc. operates online professional networking communities with career resources in the United States.
It operates through three segments: Professional Diversity Network, National Association of Professional Women (NAPW Network), and RemoteMore USA.
The company offers online professional job seeking communities that offers recruitment services, such as single and multiple job postings, recruitment media, talent recruitment communities, corporate memberships, hiring campaign marketing and advertising, e-newsletter marketing, and research and outreach services to various cultural groups and employers.
It also provides consumer advertising and consumer marketing solutions through advertising and job postings on its websites; and contracted software development services.
In addition, the company offers IAW Leadership Lab which provides virtual networking roundtable events; Professional Identity Management through the NAPW network website and members creates, manages, and shares professional identity online and promote themselves and businesses; monthly newsletters, online and in-person seminars, webinars and certification courses to develop their skills and expand their knowledge base; and additional promotional, and publicity tools, as well as free access for the member to national summits, education programs, and press release package.
Further, the company provides NAPW network members exclusive discounts on third-party products and services; and IAW Global Women's Network, which offers in-person and online networking with like-minded women to foster enhanced career connections and opportunities.
Additionally, it offers companies with engineers to provide solutions to their software needs.
Professional Diversity Network, Inc. was incorporated in 2003 and is headquartered in Chicago, Illinois.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases.
The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases.
It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation.
The company was incorporated in 2005 and is headquartered in Austin, Texas.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial.
Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, TheU. S.
Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute.
The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types.
The company was founded in 2007 and is headquartered in San Diego, California.
Sachem Capital Corp. operates as a real estate finance company in the United States.
The company engages in the originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property.
It offers short term loans to real estate investors or developers to fund its acquisition, renovation, rehabilitation, development, and/or improvement of residential or commercial properties.
The company has elected to be taxed as a real estate investment trust.
As a result, it would not be subject to corporate income tax on that portion of its net income that is distributed to shareholders.
The company was founded in 2010 and is based in Branford, Connecticut.
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems.
The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.
It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis.
Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University.
The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021.
Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Computer Programs and Systems, Inc. provides healthcare information technology solutions and services in the United States and the Caribbean nation of St. Maarten.
Its software systems include patient management software that enables a hospital to identify a patient at various points in the healthcare delivery system, as well as to collect and maintain patient information throughout the process of patient care; and financial accounting software, which offers business office applications to track and coordinate information needed for managerial decision-making.
The company also provides clinical software that automates record keeping and reporting for various clinical functions, including laboratory, radiology, physical therapy, respiratory care, and pharmacy; patient care applications; and enterprise applications that support its products for use in various areas of the hospital.
In addition, it offers Centriq, an intuitive user interface to centralize data from various care areas that provide the end user with a tool to view past and present patient information.
Further, the company provides post-acute care software systems; software application support, hardware maintenance, and education and related services; post-acute care support and maintenance services; revenue cycle management products and services, consulting and business management services, and managed information technology services; patient engagement, and encoder solutions.
It serves community hospitals and physician clinics, skilled nursing, and assisted living facilities.
Computer Programs and Systems, Inc. was founded in 1979 and is headquartered in Mobile, Alabama.
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs.
The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 dose expansion clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 dose escalation clinical trial.
It also involves in developing two earlier stage preclinical candidates, including XMT-2068 and XMT-2175.
It has strategic research and development collaborations with Janssen Biotech, Inc., Ares TradingS. A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates.
The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005.
Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata.
In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform.
The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Luminar Technologies, Inc., an automotive technology company, provides sensor technologies and software for passenger cars and commercial trucks in North America, the Asia Pacific, Europe, and the Middle East.
It operates in two segments, Autonomy Solutions and Advanced Technologies and Services.
The Autonomy Solutions segment designs, manufactures, and sells laser imaging, detection, and ranging sensors or lidars, as well as related perception and autonomy software solutions primarily for original equipment manufacturers in the automobile, commercial vehicle, robo-taxi, and adjacent industries.
The Advanced Technologies and Services segment develops application-specific integrated circuits, pixel-based sensors, and advanced lasers.
This segment also designs, tests, and provides consulting services for non-standard integrated circuits for use in automobile and aeronautics sector, as well as government spending in military and defense activities.
The company was founded in 2012 and is headquartered in Orlando, Florida.
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology.
It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors.
Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma.
It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate.
Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R for the treatment of Thyroid Eye Disease (TED), which is in Phase 2.
Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
VCI Global Limited, together with its subsidiaries, provides business and technology consulting services in Malaysia.
The company offers business strategy consultancy services, including listing solutions, investors relations, and boardroom strategies consultancy.
It also provides technology consultancy services and solutions, such as digital development, fintech solution, and software solutions.
In addition, the company engages in corporate and business advisory services in corporate finance, corporate structuring and restructuring, equity investment, and merger and acquisition; listings on recognized stock exchanges; fintech advisory; technology development; and computer software programming.
Further, it is involved in provision of artificial intelligence; image processing; communication; networking and process control software services; money lending services; education and training services; real estate management consultancy services; and leasing and operational management of resort properties.
The company serves its products to small-medium enterprises and government-linked agencies, as well as to publicly traded conglomerates across various industries.
VCI Global Limited was founded in 2013 and is headquartered in Kuala Lumpur, Malaysia.
Simpple Ltd. provides advanced technology solutions in Singapore.
The company engages in the sale, warranty, and maintenance of autonomous robotic cleaning equipment.
It also offers SIMPPLE Ecosystem platform includes SIMPPLE Software, a software platform comprising modules related to quality management, workflow management, and people management; SIMPPLE PLUS, which offers complimentary peripherals, such as IoT sensors and robotic solutions that add value to the entire ecosystem that the company distributes, sells, and manages; and SIMPPLE.AI, a next generation facilities management autonomic intelligence engine that automates robotic and human workforce deployments.
In addition, the company provides professional services, including set-up, testing, training, and commissioning, as well as recurring software-as-a-Service user license subscription fees.
It serves building service contractors, facility management companies, and building owners.
The company was founded in 2016 and is headquartered in Singapore.
Simpple Ltd. is a subsidiary of Ifsc Founders Pte.
Ltd.
Canoo Inc., a mobility technology company, designs, develops, markets, and manufactures electric vehicles for consumer, commercial fleet, government, and military customers in the United States. the company utilizes its multi-purpose platform architecture, a self-contained, fully functional rolling chassis that directly houses the critical components for operation of an electric vehicle, including its in-house designed proprietary electric drivetrain, battery systems, advanced vehicle control electronics and software, and other critical components.
It offers lifestyle delivery vehicles, lifestyle vehicles, multi-purpose delivery vehicles, and pickups; battery modules; and engineering services.
In addition, the company provides digital ecosystem, a suite of products and software tools comprising CanooHub, a web-based fleet management portal; driver mobile app for real-time vehicle status and access to remote commands; vehicle human machine interface that encompasses vehicle controls, customizable settings, range mode, cruise control, vehicle alerts, camera feeds for safety and connectivity, such as cellular, Wi-Fi and Bluetooth, as well as data and analytics infrastructure.
Canoo Inc. was founded in 2017 and is headquartered in Torrance, California.
On January 17, 2025, Canoo Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in theU. S.
Bankruptcy Court for the District of Delaware.
GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States.
It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.
The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021.
GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases.
Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
CosanS. A. engages in the fuel distribution business.
It operates through RaÃzen, Compass, Moove, Rumo, and Radar segments.
The company's RaÃzen segment engages in the production, commercialization, origination, and trading of ethanol, bioenergy, renewable sources, and sugar; trading and resale of electricity; and distribution and commercialization of fuels and lubricants.
Its Compass segment distributes piped natural gas to industrial, residential, commercial, automotive, and cogeneration customers; and develops infrastructure projects in a regasification terminal, offshore gas pipeline, and thermal generation projects utilizing natural gas, as well as commercialization of electricity and natural gas.
The company's Moove segment produces and distributes lubricants under the Comma brand.
Its Rumo segment provides logistics services for rail transportation, port storage, and loading of goods, including grains and sugar; and leases locomotives, wagons, and another railroad equipment, as well as operates containers.
The company's Radar segment manages agricultural property.
It operates in Brazil, England, France, Spain and Portugal, Argentina, Bolivia, Uruguay and Paraguay, the United States, Asia, and internationally.
CosanS. A. was founded in 1936 and is headquartered in São Paulo, Brazil.
First Foundation Inc., together with its subsidiaries, provides banking services, investment advisory, wealth management, and trust services to individuals, businesses, and other organizations in the United States.
The company operates in two segments, Banking and Wealth Management.
It offers a range of deposit products, including personal and business checking accounts, savings accounts, interest-bearing demand deposit accounts, money market accounts, and time certificate of deposits; and loan products consisting of multifamily and single family residential real estate loans, commercial real estate loans, commercial term loans, and line of credits, as well as consumer loans, such as personal installment loans and line of credits, and home equity line of credits.
The company provides various specialized services comprising trust services, online and mobile banking, remote deposit capture services, merchant credit card services, ATM cards, Visa debit cards, and business sweep accounts, as well as insurance brokerage services and equipment financing solutions.
In addition, it offers investment management and financial planning services; financial, investment, and economic advisory and related services; and treasury management services, such as bill pay, check/payee/ACH positive pay, wire origination, internal and external transfers, account reconciliation reporting, mobile deposit, lockbox, cash vault services and merchant processing.
Further, the company provides support services, including the processing and transmission of financial and economic data for charitable organizations.
It operates through a network of branch offices and loan production offices.
The company was founded in 1985 and is headquartered in Dallas, Texas.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma.
The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM.
Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia.
In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia.
BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
It also advanced TS-102 into IND-enabling activities.
In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors.
It has collaborations with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform.
TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Equity Commonwealth (NYSE: EQC) is a Chicago based, internally managed and self-advised real estate investment trust (REIT) with commercial office properties in the United States.
EQC's portfolio is comprised of four properties totaling 1.5 million square feet.
This website uses cookies. To learn more about cookies, please see our privacy policy .